Palatin Technologies (PTN) Receivables (2011 - 2025)

Palatin Technologies' (PTN) quarterly Receivables came in at $2.0 million in Q4 2025, down 71.33% on a QoQ basis from $6.9 million in Q3 2025.

Palatin Technologies (PTN) Receivables (2011 - 2025) Analysis & Trends

Palatin Technologies (PTN) has 11 years of Receivables data on file, last reported at $2.0 million in Q4 2025.

Quarterly Receivables changed N/A year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (changed N/A YoY) and the FY2025 annual result came in at $29468.0, changed N/A from the prior year.
Receivables retreated to $2.0 million in Q4 2025, from $6.9 million in the prior quarter.
In the past five years, Receivables ranged from a high of $6.9 million in Q3 2025 to a low of $29468.0 in Q2 2025.
A 4-year average of $2.5 million and a median of $1.9 million in 2021 frame the typical range for Receivables.
Annual changes were most pronounced in 2021 — Receivables sank 87.7% — and 2022, when it surged 1009.95%.
Tracing PTN's Receivables over 4 years: stood at $583991.0 in 2021, then surged by 1009.95% to $6.5 million in 2022, then slumped by 63.8% to $2.3 million in 2023, then dropped by 15.6% to $2.0 million in 2025.
The last three Receivables figures came in at $2.0 million (Q4 2025), $6.9 million (Q3 2025), and $29468.0 (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	1.93 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Palatin Technologies	40.37 Mn	40.37 Mn	-	-

Download Data